

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia

Jan 23, 2013

Source URL: <https://prod1.novartis.com/us-en/news/media-releases/novartis-drug-exjade-first-treatment-approved-fda-chronic-iron-overload-patients-non-transfusion-dependent-thalassemia-0>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/novartis-drug-exjade-first-treatment-approved-fda-chronic-iron-overload-patients-non-transfusion-dependent-thalassemia-0>